AIM
FPRX

Alambic Investment Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Alambic Investment Management’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-59,261
Closed -$272K – 303
2019
Q4 		$272K Buy
59,261
+33,761
+132% +$134K 0.23% 175
2019
Q3 		$99K Buy
25,500
+14,100
+124% +$77.4K 0.07% 266
2019
Q2 		$69K Buy
+11,400
New +$109K 0.04% 278
2018
Q3 		– Sell
-22,217
Closed -$351K – 399
2018
Q2 		$351K Buy
+22,217
New +$388K 0.1% 249
2016
Q2 		– Sell
-5,200
Closed -$211K – 603
2016
Q1 		$211K Buy
+5,200
New +$179K 0.07% 393

Other funds holding FPRX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Alambic Investment Management's FPRX Position: Q1 2020 in Review

Alambic Investment Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2020, closing a stake of 59,261 shares — an estimated $272K sold.

Alambic Investment Management first reported a position in FPRX in Q1 2016 and held it in 5 quarters. The position peaked at $351K in Q2 2018. 87 funds tracked by Wall St. Rank hold FPRX as of Q1 2020.

  • Alambic Investment Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2020 after selling out during the quarter.
  • Alambic Investment Management sold 59,261 Five Prime Therapeutics, Inc. shares in Q1 2020, an estimated $272K.
  • Alambic Investment Management first reported a position in Five Prime Therapeutics, Inc. in Q1 2016 and held it in 5 quarters.
  • Alambic Investment Management's Five Prime Therapeutics, Inc. position peaked at $351K in Q2 2018.
  • 87 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2020.

Based on Alambic Investment Management's 13F filing for Q1 2020, filed 11 May 2020.